Endologix

Endologix, founded in 1992, is a specialized medical device company dedicated to developing and providing innovative, minimally invasive technologies for the treatment of aortic disorders. The company's core focus lies in endovascular stent-grafts designed for abdominal aortic aneurysms (AAA), aiming to improve patient outcomes through advanced therapeutic solutions. Operating within the Medical Devices & Equipment and Manufacturing industries, Endologix has established a significant presence with 9 locations globally. The company employs between 500-1,000 individuals, contributing to its operational capacity and market reach. Its product portfolio includes key technologies such as the Ovation and PowerLink systems, underscoring its commitment to pioneering endovascular approaches in vascular care. Endologix's strategic focus on minimally invasive treatments positions it as a key player in a competitive market, striving to offer effective solutions for complex vascular conditions. The company's dedication to innovation is evident in its continuous development of endovascular technologies aimed at addressing critical patient needs in aortic disease management. Meet Endologix's team to learn more about their leadership and operational expertise. The company has secured substantial funding, including a $170 million debt round in 2017 and other significant issuances, supporting its growth and research initiatives. With a reported revenue of $261.2M, Endologix demonstrates considerable financial standing within the medical technology sector. Its competitive landscape includes firms like LeMaitre Vascular, Glaukos Corp, and NuVasive, highlighting the dynamic nature of the medical device market. Investors have supported Endologix through various funding rounds, reflecting confidence in its technology and market potential. Explore financial highlights for a detailedView more...